FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361834873> ?p ?o ?g. }

• W4361834873 abstract "<div>AbstractPurpose:<p>The PI3K pathway is dysregulated in the majority of triple-negative breast cancers (TNBC), yet single-agent inhibition of PI3K has been ineffective in TNBC. PI3K inhibition leads to an immediate compensatory upregulation of the Wnt pathway. Dual targeting of both pathways is highly synergistic against TNBC models <i>in vitro</i> and <i>in vivo</i>. We initiated a phase I clinical trial combining gedatolisib, a pan-class I isoform PI3K/mTOR inhibitor, and cofetuzumab pelidotin, an antibody–drug conjugate against the cell-surface PTK7 protein (Wnt pathway coreceptor) with an auristatin payload.</p>Patients and Methods:<p>Participants (pt) had metastatic TNBC or estrogen receptor (ER) low (ER and PgR < 5%, HER2-negative) breast cancer, and had received at least one prior chemotherapy for advanced disease. The primary objective was safety. Secondary endpoints included overall response rate (ORR), clinical benefit at 18 weeks (CB₁₈), progression-free survival (PFS), and correlative analyses.</p>Results:<p>A total of 18 pts were enrolled in three dose cohorts: gedatolisib 110 mg weekly + cofetuzumab pelidotin 1.4 mg/kg every 3 weeks (<i>n</i> = 4), 180 mg + 1.4 mg/kg (<i>n</i> = 3), and 180 mg + 2.8 mg/kg (<i>n</i> = 11). Nausea, anorexia, fatigue, and mucositis were common but rarely reached ≥grade 3 severity. Myelosuppression was uncommon. ORR was 16.7% (3/18). An additional 3 pts had stable disease (of these 2 had stable disease for >18 weeks); CB₁₈ was 27.8%. Median PFS was 2.0 months (95% confidence interval for PFS: 1.2–6.2). Pts with clinical benefit were enriched with genomic alterations in the PI3K and PTK7 pathways.</p>Conclusions:<p>The combination of gedatolisib + cofetuzumab pelidotin was well tolerated and demonstrated promising clinical activity. Further investigation of this drug combination in metastatic TNBC is warranted.</p></div>" @default.
• W4361834873 created "2023-04-05" @default.
• W4361834873 creator A5006346528 @default.
• W4361834873 creator A5009816526 @default.
• W4361834873 creator A5049097819 @default.
• W4361834873 creator A5049263574 @default.
• W4361834873 creator A5053390874 @default.
• W4361834873 creator A5064024878 @default.
• W4361834873 creator A5064891388 @default.
• W4361834873 creator A5066378604 @default.
• W4361834873 creator A5068666503 @default.
• W4361834873 creator A5076252332 @default.
• W4361834873 creator A5080410100 @default.
• W4361834873 date "2023-03-31" @default.
• W4361834873 modified "2023-09-27" @default.
• W4361834873 title "Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer" @default.
• W4361834873 doi "https://doi.org/10.1158/1078-0432.c.6532511.v1" @default.
• W4361834873 hasPublicationYear "2023" @default.
• W4361834873 type Work @default.
• W4361834873 citedByCount "0" @default.
• W4361834873 crossrefType "posted-content" @default.
• W4361834873 hasAuthorship W4361834873A5006346528 @default.
• W4361834873 hasAuthorship W4361834873A5009816526 @default.
• W4361834873 hasAuthorship W4361834873A5049097819 @default.
• W4361834873 hasAuthorship W4361834873A5049263574 @default.
• W4361834873 hasAuthorship W4361834873A5053390874 @default.
• W4361834873 hasAuthorship W4361834873A5064024878 @default.
• W4361834873 hasAuthorship W4361834873A5064891388 @default.
• W4361834873 hasAuthorship W4361834873A5066378604 @default.
• W4361834873 hasAuthorship W4361834873A5068666503 @default.
• W4361834873 hasAuthorship W4361834873A5076252332 @default.
• W4361834873 hasAuthorship W4361834873A5080410100 @default.
• W4361834873 hasConcept C121608353 @default.
• W4361834873 hasConcept C126322002 @default.
• W4361834873 hasConcept C143998085 @default.
• W4361834873 hasConcept C2780110267 @default.
• W4361834873 hasConcept C530470458 @default.
• W4361834873 hasConcept C71924100 @default.
• W4361834873 hasConceptScore W4361834873C121608353 @default.
• W4361834873 hasConceptScore W4361834873C126322002 @default.
• W4361834873 hasConceptScore W4361834873C143998085 @default.
• W4361834873 hasConceptScore W4361834873C2780110267 @default.
• W4361834873 hasConceptScore W4361834873C530470458 @default.
• W4361834873 hasConceptScore W4361834873C71924100 @default.
• W4361834873 hasLocation W43618348731 @default.
• W4361834873 hasOpenAccess W4361834873 @default.
• W4361834873 hasPrimaryLocation W43618348731 @default.
• W4361834873 hasRelatedWork W1966181922 @default.
• W4361834873 hasRelatedWork W1999292713 @default.
• W4361834873 hasRelatedWork W2050936961 @default.
• W4361834873 hasRelatedWork W2101673433 @default.
• W4361834873 hasRelatedWork W2317787856 @default.
• W4361834873 hasRelatedWork W2366029130 @default.
• W4361834873 hasRelatedWork W2376078656 @default.
• W4361834873 hasRelatedWork W2554176272 @default.
• W4361834873 hasRelatedWork W3005028195 @default.
• W4361834873 hasRelatedWork W80971072 @default.
• W4361834873 isParatext "false" @default.
• W4361834873 isRetracted "false" @default.
• W4361834873 workType "article" @default.